Spironolactone Attenuates Experimental Uremic Cardiomyopathy by Antagonizing Marinobufagenin

Spironolactone has been noted to attenuate cardiac fibrosis. We have observed that the cardiotonic steroid marinobufagenin plays an important role in the diastolic dysfunction and cardiac fibrosis seen with experimental renal failure. We performed the following studies to determine whether and how s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tian, Jiang, Shidyak, Amjad, Periyasamy, Sankaridrug M., Haller, Steven, Taleb, Mohamed, El-Okdi, Nasser, Elkareh, Jihad, Gupta, Shalini, Gohara, Sabry, Fedorova, Olga V., Cooper, Christopher J., Xie, Zijian, Malhotra, Deepak, Bagrov, Alexei Y., Shapiro, Joseph I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2783263/
https://ncbi.nlm.nih.gov/pubmed/19884563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/HYPERTENSIONAHA.109.140038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados